



BELRISE INDUSTRIES LIMITED

CIN : L73100MH1996PLC102827

Registered Office: Plot No. D-39, MIDC Area, Waluj, Chhatrapati Sambhajnagar Maharashtra- 431133
Phone No. 0240 255 1206, Website: www.belriseindustries.com, Email : complianceofficer@belriseindustries.com

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED ON MARCH 31, 2026

- The audited standalone and consolidated financial results of the Company for the quarter and financial year ended March 31, 2026 ("financial results") have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 24, 2026. The Statutory Auditors of the Company have provided their audit report on these financial results with an unmodified opinion. The consolidated financial results includes results of the Company's wholly owned subsidiaries and step down subsidiaries in India, United Arab Emirates, France and UK.
- The Board of Directors of the Company has recommended a dividend of @11% (Rs. 0.55 per equity share) of face value Rs. 5 each in respect of the year ended 31st March, 2026, subject to approval of members in ensuing Annual General Meeting.
- The financial results have been filed with the Stock Exchanges (NSE and BSE) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"). The full format of the financial results is available on the Company's website i.e. <http://www.belriseindustries.com> and on the website of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com. The same can be accessed by scanning the QR Code provided below.



By or on behalf of Board of Directors
Belrise Industries Limited
Sd/-
Shrikant Shankar Badve
Managing Director
DIN : 00295505

Place : Pune
Date : May 24, 2026



EYANTRA VENTURES LIMITED

CIN: L72100TG1984PLC167149

Regd. Office: 301, 3rd Floor, CSR Estate, Plot No. 8, Sector - 1, HUDA Techno Enclave, Madhapur Main Road, Hyderabad -500081, Telangana, India. Ph. No: +91-7702974403, Email ID: support@eyantraventures.com

STANDALONE AND CONSOLIDATED AUDITED FINANCIAL RESULTS OF EYANTRA VENTURES LIMITED (COMPANY) FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2026.

The Board of Directors of the Company at their meeting held on May 25, 2026, have approved the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.

The aforementioned financial results along with Audit Reports issued by the Statutory Auditor of the Company are available on Company's website at <https://eyantraventures.com/result-announcement/> and can also be accessed by scanning the Quick Response (QR) Code given below:



Place : Hyderabad
Date : May 25, 2026

By Order of the Board
For EYANTRA VENTURES LIMITED
Sd/-
Vinita Raj Narayanam
Chairperson and Managing Director
DIN: 09319780



SUDARSHAN CHEMICAL INDUSTRIES LIMITED

Regd. Office / Global Head Office : 7th Floor, Eleven West Panchshil, Survey No. 25, Near Pan Card Club Road, Baner, Pune - 411 069, Maharashtra, India Tel. : +91 20 68281200 Email : shares@sudarshan.com
Website : www.sudarshan.com CIN : L24119PN1951PLC008409

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2026

₹ in crore

Sr. No.	Particulars	Standalone			
		Quarter Ended		Year Ended	
		31.03.2026 (Audited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Revenue from operations	732.7	703.6	2,396.7	2,533.9
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	129.8	43.6	350.5	212.4
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	135.2	33.9	329.4	194.2
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	120.4	22.4	290.3	140.9
5	Total Comprehensive Income for the period / year [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	132.2	25.2	308.7	152.2
6	Paid-up equity share capital (Face Value ₹ 2/- per share)	15.7	15.7	15.7	15.7
7	Reserve excluding Revaluation Reserves as shown in the Audited Balance Sheet of the previous year	-	-	2,518.2	2,243.2
8	Net Worth	2,533.9	2,258.9	2,533.9	2,258.9
9	Earnings per share (of ₹ 2/- each) (before exceptional item)				
	Basic Earnings Per Share	14.6	4.2	39.6	22.5
	Diluted Earnings Per Share	14.6	4.2	39.5	22.4
10	Earnings per share (of ₹ 2/- each) (after exceptional item)				
	Basic Earnings Per Share	15.3	2.9	36.9	19.9
	Diluted Earnings Per Share	15.3	2.9	36.9	19.9
		Not annualised			

Sr. No.	Particulars	Consolidated			
		Quarter Ended		Year Ended	
		31.03.2026 (Audited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Revenue from operations	2,789.9	1,349.4	9,787.2	3,345.6
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	146.6	69.3	157.0	200.0
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	167.7	10.6	156.6	99.3
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	82.5	0.4	40.8	60.3
5	Total Comprehensive Income for the period / year [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	149.8	1,178.4	121.8	1,248.0
6	Paid-up equity share capital (Face Value ₹ 2/- per share)	15.7	15.7	15.7	15.7
7	Reserve excluding Revaluation Reserves as shown in the Audited Balance Sheet of the previous year	-	-	3,434.5	3,376.7
8	Net Worth	3,854.0	3,990.6	3,854.0	3,990.6
9	Earnings per share (of ₹ 2/- each) (before exceptional item)				
	Basic Earnings Per Share	8.0	7.6	6.6	22.5
	Diluted Earnings Per Share	8.0	7.6	6.6	22.5
10	Earnings per share (of ₹ 2/- each) (after exceptional item)				
	Basic Earnings Per Share	10.0	(0.5)	2.8	7.9
	Diluted Earnings Per Share	10.0	(0.5)	2.8	7.9
		Not annualised			

NOTES :

- The above audited financial results were reviewed by the Audit Committee and approved and taken on record by the Board of Directors at their respective meetings held on 25th May, 2026. These audited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind-AS") as specified under Section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) and the provisions of the Companies Act, 2013.
- The audited consolidated financial results include the financial results of the Holding Company and its subsidiaries, step down subsidiaries and joint ventures.
- On 21st November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Group has assessed and disclosed the incremental impact of these changes and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Group has presented such impact as "Statutory impact of new Labour Codes" under "Exceptional items income / (expense)" in the consolidated financial results for the year ended 31st March 2026. The impact consisting of gratuity of (₹ 30.1 crores) and long-term compensated absences of (₹ 1.9 crores) primarily arises due to change in wage definition. The Group continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- The Board of Directors have recommended a dividend of ₹ 5/- per share on face value of ₹ 2/- per share (i.e. 250%) for the financial year 2025-26, which is subject to approval of shareholders at the 75th Annual General Meeting of the Company.
- The Board of Directors of Sudarshan Europe B.V. ("SEBV") (wholly owned subsidiary of Sudarshan Chemical Industries Limited) at its meeting held on 8th October 2024 provided its in-principle approval for the acquisition of global pigment business operations of the Heubach Group of Germany through an asset and share deal, subject to completion of customary conditions and receipt of requisite regulatory approvals. Pursuant to this, SEBV has entered into a definitive agreement in relation to the said proposed acquisition on 11th October 2024.
The said acquisition was completed on 3rd March 2025 ("Closing Date") by SEBV for a preliminary purchase consideration of € 151.9 million (approx. ₹ 1,389.9 crores) which was subsequently finalised at € 139.6 million (approx. ₹ 1,277.0 crores) during the "measurement period" as per Ind AS 103: "Business Combinations" in line with the Purchase and Transfer Agreement. The acquisition was financed through a combination of external funds raised by the Holding Company and borrowings availed by SEBV. Transaction and other incidental costs with respect to the aforesaid acquisition incurred up to 31st March 2025 of ₹ 103.6 crores have been disclosed as "Exceptional items income / (expense)".
As at the Closing Date, the fair value of assets and liabilities acquired have been determined by the Group and accounted for using the acquisition method of accounting in accordance with Ind AS 103: "Business Combinations".
During the year ended 31st March 2026, the Company completed the purchase price allocation exercise within the measurement period. Accordingly, adjustments have been made to the provisional amounts recognised earlier, same have resulted in a decrease in capital reserve as on the Closing Date from ₹ 1,243.9 crores to ₹ 1,196.3 crores, which has been adjusted retrospectively. Comparative information has been restated accordingly.
Resultant impact pertaining to above changes in fair value have been retrospectively adjusted in 'Gain on bargain purchase', 'Cost of materials consumed' and 'Changes in inventories of finished goods and work-in-progress' in the consolidated results of the Group for the year ended March 31, 2025.
- The above is an extract of the detailed format of Quarterly / Annual Financial Results as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid Audited Financial Results will be uploaded on the Company's website www.sudarshan.com and will also be available on the websites of BSE Limited www.bseindia.com and The National Stock Exchange of India Limited www.nseindia.com for the benefit of shareholders and investors.

For and on behalf of the Board of Directors

R.B.RATHI
CHAIRMAN & MANAGING DIRECTOR
DIN: 00018628

Place : Pune
Date : 25th May 2026

BLUE JET HEALTHCARE LIMITED



Registered and Corporate Office: 701, 702, 7 Floor, Bhurniraj Costarica, Sector 18, Sanpada, Navi Mumbai, Thane - 400 705, Maharashtra, India.
E-mail: companysecretary@bluejethealthcare.com
Website: www.bluejethealthcare.com. Telephone: +91 (22) 69891200;
Corporate Identity Number: L99999MH1968PLC014154

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THREE MONTHS AND YEAR ENDED MARCH 31, 2026

Sr. No.	Particulars	Three Months Ended			Year Ended	Year Ended
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Total Income from Operations	2,575.88	2,056.23	3,526.70	10,159.75	10,762.41
2	Net Profit/ (Loss) for the period (before Tax, Exceptional Items)	871.49	537.77	1,472.12	3,325.12	4,060.99
3	Net Profit/ (Loss) for the period before tax (after Exceptional Items)	871.49	537.77	1,472.12	3,325.12	4,060.99
4	Net Profit/ (Loss) for the period after tax (after Exceptional Items)	643.44	401.66	1,100.95	2,478.16	3,052.03
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	644.39	397.62	1,101.27	2,476.18	3,052.35
6	Paid-up Equity Share Capital (Face Value ₹ 2 per share)	346.93	346.93	346.93	346.93	346.93
7	Reserves (Excluding Revaluation Reserve as Shown in the Balance Sheet of Previous Year)				13,252.19	10,984.18
8	Earnings per Share (EPS) of Face value ₹ 2/- each*					
	(a) Basic - (₹)	3.71	2.32	6.35	14.29	17.59
	(b) Diluted - (₹)	3.71	2.32	6.35	14.29	17.59

Notes:

- The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results of the company are available on the Stock Exchange websites viz. www.bseindia.com, www.nseindia.com and also on the company's website www.bluejethealthcare.com.
- The above financial results of the Company for the three months and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on May 25, 2026. Further, the above financial results have been audited by the Statutory Auditor of the Company.

For and on behalf of Board of Directors
Sd/-
Shiven Arora
Managing Director
DIN: 07351133
Place: Navi Mumbai
Date: May 25, 2026



J.B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : 302, Iscon Mall, Star India Bazar Building, Opp. Jodhpur BRTS Satellite, Ahmedabad - 380 015
Corporate Office: Energy IT Park, Unit A2, 3rd Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400 025.
Phone: 022-2439 5200 / 2439 5500
CIN : L24390GJ1976PLC173077 Website: www.jbpharma.com E-mail : investorrelations@jbpharma.com

NOTICE

NOTICE is hereby given that the 50th Annual General Meeting (AGM) of the Company will be held through VC/OAVM on Wednesday, June 17, 2026 at 3.00 p.m. (IST), in compliance with the applicable provisions of the Companies Act, 2013, and the Rules made thereunder and the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), read with General Circular No. 3/2025 dated September 22, 2025, General Circular No. 20/2020 dated May 5, 2020, General Circular No. 14/2020 dated April 8, 2020 and General Circular No.17/2020 dated April 13, 2020 and other applicable circulars issued by the Ministry of Corporate Affairs ('MCA'), Government of India, to transact the businesses as set out in the notice of the AGM dated May 11, 2026.

In terms of MCA circulars and circulars/master circular issued by SEBI, Notice of the AGM and Integrated Annual Report for the financial year 2025-26 are sent through e-mail to the members whose e-mail address is registered with the Company or the Depository Participant/depository.

The members of the Company are also hereby informed and are requested to note that:

- The businesses as set out in the aforesaid notice may be transacted by the members through remote e-voting facility (i.e. e-voting from any place). The remote e-voting facility is provided through e-voting platform of Central Depository Services (India) Limited ("CDSL") for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by the members using remote e-voting system as well as e-voting during the AGM will be provided by CDSL, as per provisions of Section 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 and provisions of the Listing Regulations;
- The remote e-voting period shall begin on Sunday, June 14, 2026 at 9.00 a.m. (IST) and will end on Tuesday, June 16, 2026 at 5.00 p.m. (IST);
- During the above voting period, shareholders of the Company holding shares on June 10, 2026, being the cut-off date, may cast their votes electronically;
- The persons who have acquired shares and become members of the Company after despatch of notice may send request to the Company at the registered office or through email to investorrelations@jbpharma.com or may refer to the copy of the notice dated May 11, 2026 convening AGM which provides details of login ID and the manner of generating password. The said notice can also be downloaded from the Company's website www.jbpharma.com and CDSL's website www.evotingindia.com. The persons who have already registered with CDSL for e-voting in past can vote using their existing password.
- The remote e-voting shall not be allowed beyond the aforesaid date and time of end of remote e-voting and e-voting module shall be disabled by CDSL for voting thereafter;
- The members attending the meeting who have not cast their votes through remote e-voting, shall only be able to exercise their right to vote during the meeting;
- A member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again during the AGM;
- A person whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as e-voting in the AGM;
- The members who have not registered their e-mail address with the Company or depository participant/depository, need to follow the following process for obtaining login credentials for remote e-voting and e-voting during the AGM:
 - Members holding shares in physical form may request for the same along with providing necessary details like Folio No., Name of Member, self-attested scan copy of PAN Card and Aadhar Card by email to investorrelations@jbpharma.com
 - Members holding shares in demat form may request for the same along with providing Demat account details (CDSL-16 digit beneficiary ID or NSDL- 8 character DPID + 8 character Client ID), Name of Member, client master or copy of Consolidated Account statement, self-attested scan copy of PAN Card and Aadhar Card by email to investorrelations@jbpharma.com
- The members who have not registered their e-mail address have to follow the following process to register the same:
 - Members holding shares in physical form - Update your email id and mobile no by providing Form ISR-1 and ISR-2 available on the website of the Company / RTA.
 - Members holding shares in demat form - Update your email id & mobile no. with your respective Depository Participant (DP); for individual members holding shares in demat form, updation of email id & mobile no. is mandatory for e-voting and joining virtual meetings through depositories
- The Notice of AGM will be available on the website of the Company at www.jbpharma.com, on website of Stock Exchanges i.e. BSE Ltd. and National Stock Exchange of India Limited. This notice will also be available on the website of CDSL at www.cdslindia.com.
- The members may refer the Frequently Asked Questions (FAQs) and e-voting manual available at www.evotingindia.com, under help section or call on toll free no.: No-1800 21 09911; and
- The members may contact Mr. Rakesh Dalvi, Sr. Manager, CDSL, A Wing, 25th Floor, Marathon Futurex, Mafatal Mills Compounds, N. M. Joshi Marg, Lower Parel (East), Mumbai 400013 or write an email to helpdesk.evoting@cdslindia.com to address grievances, if any, connected with facility of e-voting.

NOTICE is also hereby given pursuant to Section 91 of the Companies Act, 2013, that Friday, May 29, 2026 has been fixed as Record Date for equity shareholders for determining names of the members entitled to dividend, if declared at the AGM.

Place : Mumbai
Date : May 25, 2026

For J.B. Chemicals & Pharmaceuticals Ltd.
Sandeep Phadnis
Company Secretary

